This study investigated the cognitive side effects of a 6-week course of sertraline treatment on verbal memory and attention in children and adolescents. Children with various anxiety disorders (social phobia, generalized and separation anxiety disorder; n = 28), between 8 and 17 years of age, received a standardized, computerized neuropsychological assessment before treatment and another 6 weeks after treatment onset with sertraline (daily dose range between 25 and 100 mg). The patient group was compared to healthy controls (n = 28), who were matched for age and IQ and were also tested twice over a 6-week period. Sertraline did not have any negative effects on attentional performance (p > 0.05) but did increase response speed in a divided attention paradigm (p = 0.02). By contrast, performance of the interference part of a verbal memory task decreased (p = 0.05). The described results also remained stable over a 12-week period after treatment onset. Thus, the cognitive side effects of sertraline seemed to differ slightly between pediatric patients and those described in adult patient groups, should, therefore, be carefully assessed.
INTRODUCTION

S ELECTIVE SEROTONIN REUPTAKE INHIBITORS
have become the second-most prescribed psychotropic agents and represent an important therapeutic modality in the treatment of childhood psychiatric disorders (Jensen et al. 1999) . Prescription rates are not only increasing among late adolescents but also among children between 10 and 14 years of age (Zito et al. 2002) . However, the adverse effects of these drugs are poorly investigated in children and adolescents. Very recently, serious concerns arose concerning the safety of SSRI treatment in this age group owing to an increased risk of suicidal and self-harming thoughts during SSRI treatment (Roth et al. 2004) . Behavioral side effects include motor restlessness and behavioral disinhibition (Damsa et al. 2004 ). The neuropsychological side effects of SSRI have never been systematically assessed in childhood psychiatric disorders, although animal and human studies indicate that these drugs may influence cognitive performance (Buhot et al. 2000) . Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit 5-HT reuptake into the presynaptic ter-minal, resulting in an increased 5-HT concentration in the synaptic cleft (Anderson 2004) . SSRIs are effective in improving impaired cognitive functions in depressed adult patients (Ferguson et al. 2003) , in subjects with Alzheimer's disease (Meltzer et al. 1998) , and in improving language acquisition in autistic children (DeLong et al. 1998) . Impulsive behavior may be modified by serotonergic (5-HT) activity, with underactivity in 5-HT neurotransmission increasing impulsivity and vice versa (Bizot and Thiebot 1996) . By contrast, animal data and lesion studies suggested that acute increases in central serotonin concentrations may impair learning abilities (Santucci et al. 1996) . Moreover, a single-dose study with healthy adults showed that paroxetine could improve motor performance through practice but that it decreased the ability to inhibit automatisms (Loubinoux et al. 2002) . Other studies with healthy middle-aged subjects confirmed paroxetine's impairment of vigilance performance, whereas this effect was not found for sertraline (Schmitt et al. 2002) .
Taken together, the results for SSRI influence on cognitive functions, such as attention and memory, remain contradictory. In fact, different study designs (single application, various dosages, short-term versus long-term applications, different SSRIs) make it difficult to draw a clear picture of the cognitive side effects. However, the effects of manipulations of serotonergic activity seem to depend on the nature of the responses required, the baseline regulation of the serotonergic system, and the age of the subjects, thereby differentially influencing impaired and nonimpaired cognitive functions in healthy subjects and patient groups of different ages.
During school age, cognitive dysfunctions could lead to learning difficulties and serious problems at school and consequently impair social, emotional, and cognitive development. This is why the neuropsychological side effects of psychopharmacological interventions in childhood and adolescence need to be carefully assessed. Thus, our study aimed to investigate the effect of a 6-week course of sertraline treatment on verbal memory and attentional performance in children with anxiety disorders. Recently, we demonstrated that unmedicated children with anxiety disorders did not differ significantly from healthy controls in these cognitive functions (Günther et al. 2004) . Note, however, that the sample used in the previous study did partly overlap with the sample used in this study (70% of the control sample and 53% in the anxiety group). In this study, we wanted to examine the influence of sertraline on nonimpaired cognitive functions in children and adolescents treated with sertraline for clinical purposes. In 2001, when the study was designed, sertraline and fluvoxamine were the only SSRIs with proven efficacy for anxiety disorders in children and adolescents in random, controlled trials (Rynn et al. 2001 ; The Research Units on Pediatric Psychopharmacology Anxiety Study Group 2001). In addition, there were several studies demonstrating that sertraline was rather safe in the treatment of children and adolescents (Green 2001) .
METHODS
Participants and selection procedure
A total of 28 children with anxiety disorders, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV; APA 1994), plus 28 healthy controls, 8-17 years of age, participated in this study. Prior to the study, all the children underwent an extensive psychiatric examination conducted by an experienced child psychiatrist. A further psychiatric classification was then determined on the basis of a German semistructured interview with the parents and the child (K-DIPS; Unnewehr et al. 1995) performed by a second independent rater, who was blind to the first rater's diagnosis. Table 1 provides demographic details.
All children of the anxiety group were inpatients at the Department of Child and Adolescent Psychiatry (Aachen University; Aachen, Germany). In all patients, the disorder interfered significantly with the person's normal routine, academic functioning, and social activities, and outpatient treatment was no longer sufficient. The primary diagnoses for hospitalization were social phobia (n = 19; DSM-IV: 300.23), generalized anxiety disorder (n = 4; 300.02), and separation anxiety disorder (n = 5; 309.21). In addition, other comorbid anxiety disorders were identified, such as specific phobia (n = 11; 300.29), generalized anxiety disorder (n = 1; 300.02), panic disorder with agoraphobia (n = 3; 300.01) and without agoraphobia (n = 1; 300.21), separation anxiety disorder (n = 1; 309.21), and obsessive-compulsive disorder (n = 1; 300.3). Eleven children had no other comorbid anxiety disorder, and 5 children had more than one. Exclusion criteria were a general IQ below 80 (WISC-III; Tewes et al., 2000) , any kind of psychotropic medication prior to the study, and a present or past diagnosis of attention-deficit/hyperactivity disorder (ADHD). Affective disorders were not considered to be exclusion criteria because of the high comorbidity between anxiety and depressive disorders in children (Angold et al. 1999; Eley and Stevenson 1999) . Comorbid affective disorders were dysthymic disorder (n = 1; DSM-IV: 300.4) and major depression with a recent episode of minor severity (n = 12; DSM-IV: 296.21) in the anxiety group. Of the 28 patients, 11 were male and 17 were female. The 28 participants in the control group (12 male, 16 female) had no history of psychiatric diagnosis. The two groups were not different with respect to gender distribution ( 2 (1) = 0.74; p = ns), age (t (54) = 0.78; p = ns) and IQ (t (54) = 1.48; p = ns). However, as expected, a significant difference was found on the child depression inventory (DIKJ; Kovacs 1985; StiensmeierPelster et al. 2000 ) F (1/54) = 25; p < 0.001) and the state version of the German State-Trait Anxiety Inventory for Children (STAIK; Joormann and Unnewehr 2003); F (1/54) = 13.5; p = 0.001). Informed parental consent was obtained for all participants, and the study was approved by the Ethics Committee of the University Hospital Aachen (Aachen, Germany).
Medication protocol
The anxiety group received sertraline as part of a standardized treatment program, including parental education, as well as single and group therapy. The daily doses of sertraline varied between 25 mg and 100 mg (mean doses = 58.1 mg; SD = 13.7). There was no difference in mean dosage between the anxiety group (mean = 58.3 ± 12.2 mg) and children with anxiety disorder and comorbid depressive disorder (mean = 57.7 ± 15.8 mg).
After 6 weeks, a standardized psychiatric examination (including a psychopathological assessment) was conducted by a senior child psychiatrist (KH), and all patients included in our study showed a clinically relevant improvement of their anxiety symptoms compared to the baseline assessment. In addition, DIKJ scores significantly improved after 6 weeks of SSRI treatment in the patient group (F (1/54) = 12; p = 0.001), while no significant change was detected in the STAIK scores (F (1/54) = 0.41; ns). The state version was used, because state anxiety is strongly related to task performance (e.g., Kelly 2002; Schell and Grasha 2000) .
Twelve children with anxiety disorder were additionally examined 12 weeks after treatment onset, again with the same sertraline dose.
All subjects received a standardized computerized neuropsychological assessment before treatment (T1) and again 6 weeks after treatment onset with sertraline (T2). Controls were also tested twice without medication 6 weeks apart. The order of the neuropsychological tests was randomized. Cognitive functions were assessed using the following tests.
Verbal memory
The Auditory-Verbal Learning Test (Helmstaedter et al. 2001; Lezak 1995) was applied with the following dependent measures:
• free recall (the score of the total words from trials 1-3); • working memory (correct words from trial 1); 610 GÜNTHER ET AL. • learning curve (the difference between trial 3 and trial 1 as an acquisition rate); • interference (trial after learning a distractive word list); • a 30-min delayed recall trial; and • a recognition trial.
Attention
Concepts of attention, in general, distinguish between selectivity and intensity of attention (Van Zomeren and Brouwer 1994) and a supervisory attentional control mechanism that modulates both the selectivity and intensity dimension (Norman and Shallice 1986) . Different computerized attention tests were selected according to a model-oriented approach in order to get a full picture of attentional performance. Alertness was assessed with a simple reaction time (RT) task (Fimm and Zimmermann 2001). The child had to respond with the dominant hand to the presence of a target stimulus. The Sustained Attention Task involved the continuous, consecutive presentation of 50 series of 12 different dot patterns 600 signals (de Sonneville 2000). In each series, an equal number of 3-, 4-, or 5-dot patterns was presented in a pseudorandom manner. The child was instructed to push the "yes" button with the dominant hand whenever a 4-dot pattern (target) were shown and to press the "no" button with the nondominant hand if the pattern contained 3 or 5 dots (nontargets). Divided Attention was a dual task that combined a visual and acoustic discrimination task (Fimm and Zimmermann 2001) . Children were asked to respond as quickly as they could whenever a square appeared and if an alternating high and deep tone was repeated. One hundred stimuli were presented, which contained 17 visual and 16 acoustic goal targets. In the Go/No-Go Paradigm (Fimm and Zimmermann 2001) that assesses response selection/ inhibition, a motor response with the dominant hand was either initiated (go) or inhibited (no-go), depending on whether an "x" (go) or a "+" (no-go) stimulus appeared. Visual stimuli appeared in random order for a duration of 200 milliseconds, with a variable inter-trial interval of a maximum of 1600 milliseconds. Fifty percent of the 40 stimuli were go trials.
In each task, the dependent measures were the reaction time (RT) and its standard deviation (SD), the number of misses, and false alarms.
The high learning effects in the verbal memory and divided attention task led to parallel versions being used in the second session.
Statistical analysis
Data were analyzed using SPSS 11 (SPSS Inc., Chicago, Illinois). Group differences on the first measurement were analyzed using multivariate analysis of covariance (MANCOVA), with the diagnostic group as the between-subject factor and the neuropsychological test scores as the dependent variables. IQ, age, or gender were included as covariates if they correlated significantly with the dependent variables (p < 0.05). Repeated measure group differences were evaluated using repeated measure analysis of covariance (ANCOVAR), with the diagnostic group as the independent variable, time of measurement as the within-subject factor, and neuropsychological test scores as the dependent variables. The long-term effects of sertraline on the 12 patients reexamined 12 weeks after treatment onset were analyzed using the Exact Wilcoxon signed rank test for paired measurements. Results with an alpha (␣) Յ0.05 were reported. It was decided not to adjust for multiple testing in order to avoid Type II errors and also to detect mild neuropsychological impairments on a more liberal level (Tabachnick and Fidell 2000) . If significant effects were detected, an ANOVA with post-hoc comparisons was conducted in order to analyze whether children with comorbid depression drive the group differences at T2. Indirect treatment effects might impact on neuropsychological task performance by enhancing clinical symptoms of anxiety and depressive mood. To control for those indirect effects, we decided in favor of the following procedure: Firstly, the effects of state anxiety and depressive mood were correlated with the dependent measures of the baseline assessment, and secondly, the change of symptoms was correlated with the change of neuropsychological task performance. Significant associations were found only between depressive symptoms, their change over time and neuropsychological measures (see Table 3 ), while this was not the case for symptoms of anxiety. Therefore, the effects of depressive symptoms (DS) and change of mood during treatment (CM) were controlled by including two covariates: The mean depressive score of the DIKJ produced by the two measurements (DS = [DIKJ1 + DIKJ2]/2) and the difference between the two measures (CM = DIKJ2 Ϫ DIKJ1).
Pearson correlations between the difference scores of the dependent measures (T1 Ϫ T2) and the dosage of sertraline were conducted to analyze dosage dependencies of the changes between baseline measures at T1 and performance at T2. All statistical tests were twotailed to detect improvements and decrements of neuropsychological test performance under sertraline medication.
RESULTS
Generally, IQ and age for both groups correlated significantly with the dependent measures of the neuropsychological tests at T1 (r > 0.2; n = 56; p < 0.05). When controlled for age and IQ, no significant group differences between the controls and the patient group were identified in verbal memory (F (6; 47) = 1.62; p = ns), divided attention (F (4; 49) = 1.15; p = ns), sustained attention (F (4; 49) = 1.26; p = ns), go/no-go paradigm (F (4; 49) = 0.94; p = ns), and alertness task (controlled only for age; F (2; 52) = 0.03; p = ns) in the multivariate comparison of the baseline measures (M1).
For descriptive purposes, correlation patterns were analyzed between clinical measures of state anxiety and mood and neuropsychological variables. No significant correlation was found between the delta score (⌬ 1-2 ) of the neuropsychological tests (difference between pre-[T1] and 6-week post-treatment [T2]) and possible covariates, such as IQ, age, and gender. Significant correlations were found between the DIKJ score and the neuropsychologicaldependent measures of verbal memory, alertness, sustained attention, and divided attention at T1. Interestingly, the direction of correlation coefficients indicated that anxious children performed better on the neuropsychological tasks if they had higher depression scores. At T2, a significant association was found only for 3 of the 20 dependent measures (see Table 3 ). A positive correlation was found between ⌬ 1-2 of the DIKJ and ⌬ 1-2 of the sustained attention task: Children with higher improvement in the DIKJ showed a larger enhancement of task performance. No significant correlations were found within the group of normal controls and between the STAIK and the dependent measures for the SSRI group. In addition, no correlation could be detected between the dosage of sertraline and changes of the dependent variables between T1 and T2 (r < 0.25; ns).
The analysis of the effect of sertraline medication on verbal memory revealed significant interaction between group and time for performance in the interference condition (F (1; 52) = 3.81; p = 0.05). While the controls improved their performance at the second measurement 612 GÜNTHER ET AL. (T1 Ϫ T2 = 0.5), the SSRI group was more susceptible to interference (T1 Ϫ T2 = Ϫ1.1). The mean change was higher in the group of children with comorbid depression (Ϫ1.6 in contrast to Ϫ0.5 in the group without depression), but the post-hoc comparison between the two clinical groups was not significant (p = 0.113; see Fig. 1 ). By contrast, no significant interaction effects were found between group and time for free recall (F (1; 52) = 0.55; p = ns), working memory (F (1; 52) = 1.18; p = ns), learning curve (F (1; 52) = 3.16; p = ns), long-delay recall (F (1; 52) = 0.1; p = ns) and recognition (F (1; 52) = 0.49; p = ns). Although the performance of the control group did not change significantly with regard to working memory, learning curve, long-delay recall, and recognition in the second session, the score for the long-delay recall and recognition decreased numerically in the SSRI group. The analysis of the attention tests resulted in a significant improvement of the SSRI group in the divided-attention paradigm for reaction time (F (1; 52) = 5.41; p = 0.024). While the control group showed a relatively stable performance at T1 and T2 (T1 Ϫ T2 = Ϫ14 milliseconds), anxious children significantly improved their performance under SSRI medication at the second measurement (T1 Ϫ T2 = 36 milliseconds). No difference could be detected between the two clinical groups in the post-hoc comparisons; but both groups improved equally. No other significant interaction effects were detected. Table 4 summarizes the results for all neuropsychological variables separately for group and time of measurement, as well as the F statistics on the interaction effects between group and time.
Twelve of the 28 patients were reexamined 12 weeks after treatment onset (T3). With a relatively liberal alpha level (␣ < 0.1), no significant differences could be found between T2 and T3 for verbal memory, alertness, sustained attention, divided attention, and go/no-go variables (Z < 1.4; ns). At T2, the patients showed an improved reaction time in the divided-attention task and no significant change between T2 and T3 (Z = 0.6; ns). Similarly, the decreased performance verbal memory interference remained stable 12 weeks after treatment onset (Z = 0.55; ns).
DISCUSSION
This study is the first to have examined neuropsychological side effects of sertraline treatment in a clinical group of children and adolescents over a period of 6-12 weeks. Depressive symptoms improved in the SSRI group, whereas no improvement was found for state markers of anxiety. Controlling for depressive symptoms and change of mood during treatment, the study showed that sertraline Comparison of the significant verbal memory and divided attention variables between controls (n = 28) and the SSRI group, which is divided in patients with anxiety disorder (n = 15) and patients with anxiety disorder with comorbid depressive disorder (n = 13), which were measured before treatment (T1) and 6 weeks after treatment onset (T2). SSRI = selective serotonin reuptake inhibitor.
in dosages of between 25 and 100 mg did not have any negative effects on attentional performance. By contrast, an increased response speed in the divided-attention paradigm emerged under SSRI medication. However, performance in the interference part of the verbal memory task deteriorated and patients were more susceptible to an interference list. These effects were found to be stable, even 12 weeks after treatment onset. The performance decrement was not driven by the comorbidity of depression, but was found in the patient group with and without comorbid depressive disorders. In addition, correlation patterns between neuropsychological task performance and self-rating scales of anxious and depressive symptoms confirmed that none of the significant SSRI effects on attention and memory could be primarily explained by change of state anxiety or depressive symptoms. The results of improved attentional performance under SSRI medication (i.e., quicker reaction time in a selective attention task) are in line with several other studies (Saletu and Grunberger 1988) in adult subjects. Interestingly, as in our study, Schmitt et al. (2002) also found no negative effect of sertraline on vigilance performance, while paroxetine did impair vigilance performance. These differential effects on attentional functions might be explained by the fact that sertraline has an additional mild dopamine-stimulating effect, which is not the case for paroxetine. So it may be speculated that the positive effects of sertraline on selective attention and the lack of a significant decline in vigilance performance may presumably be owing to the concomitant effects of sertraline on dopamine activity, counteracting the negative effects of serotonin on dopamine neurotransmission. So our data suggest that this seems to be true for children and adolescents 8-17 years of age as well. In addition, it might be possible that the improvement in reaction time is owing to clinically reduced anxiety symptoms caused by sertraline. This possibility could not be ruled out, because we only entered state anxiety in our analyses. Although, behaviorally, it has been described that SSRIs may induce disinhibitory symptoms in children and adolescents (Damsa et al. 2004 ), we did not find any deterioration of inhibitory performance (e.g., in the Go/No-Go-Task). In addition, we did not find any attentional deficit (i.e., in the alerting or the vigilance system) that may correspond to the side effect of somnolence during sertraline treatment.
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Comparison between the neuropsychological side effects found in our study and the effects described for pharmacological treatment alternatives recommended for patients with anxiety disorders indicated that the cognitive outcome seemed to be more positive for sertraline. For example, benzodiazepines, which are frequently prescribed for the pharmacological management of general symptoms of anxiety (Hollister et al. 1993) , have been described as producing cognitive impairments in attention, concentration, and short-term memory (Gale and Oakley-Browne 2000) . Side effects, such as sedation (Rickels et al. 2000) and attentional problems when compared with a placebo condition (Gould et al. 1997) , were also described for buspirone, a 5-HT 1A -agonist. Moreover, imipramine, a tricyclic antidepressant, exerts negative dose-response effects on reaction-time performance (motor speed, motor pursuit; Gualtieri and Evans 1988) . However, no direct conclusion on the comparative cognitive side effects of different pharmacological treatments can be drawn from the results of our study, but should, rather, be further addressed in future double-blind, placebo controlled medication studies that directly compare the effects of different drugs.
In contrast to these positive effects of sertraline on attentional performance in pediatric patients, the effects on memory function-in particular, under complex and distracting conditions (such as in the interference part)-are more worrying. It is also necessary to consider that learning under distracting circumstances and distinguishing between important and unimportant information is one of the key abilities needed in school and may, therefore, considerably impact school performance in children and adolescents. At first glance, this result seemed to be contradictory to most of the results obtained from adult studies. For example, some studies claimed facilitation of memory consolidation (Harmer et al. 2002) or no change of memory functions in healthy subjects (Schmitt et al. 2001; Siepmann et al. 2003) and adult patients (Amado-Boccara et al. 1995; Ferguson et al. 2003) under SSRI medication. Vythilingam et al. (2004) even demonstrated that impaired memory functions in adults with major depressive disorders were improved after treatment with the SSRI fluoxetine (e.g., verbal immediate and delayed recall), although, in this study, the enhanced memory functions could also be the result of improved depressive symptomatology. However, it should be considered that SSRI effects on memory functioning might differ between children and adults owing to differences in neural representation-in particular, in the prefrontal cortex (HAROLD model; Cabeza 2002) .
In their review, Masand and Gupta (1999) summarize that memory impairment might be one of the possible side effects of SSRIs, but suggest that this is a result of an initial effect of the medication and that it disappears after waiting for tolerance. In our study, however, this negative effect remained stable, even after 12 weeks of treatment. In line with this, some patients in our study reported being forgetful under SSRI medication. However, this adverse SSRI effect on memory function in our study was rather small and would not have survived on a more conservative alpha level. In addition, according to the existing norms of the Auditory-Verbal Learning Test (Helmstaedter et al. 2001) , the mean test scores under sertra-line in the patients group were still within the normal variation, and none of the patients scored within the abnormal range of clincial signifcance (T-score under 35). Thus, the clinical impact of this performance decrement has to be carefully weighed up against the positive treatment effects of sertraline.
CONCLUSIONS
Taken together, this study marked a first step towards investigating the influence of SSRIs on cognition in children and adolescents. The lack of a placebo control and the open design of this study limit the conclusions that can be drawn from this report. Thus, double-blind, placebo-controlled acute and continuation studies of sertraline (and other SSRIs) in children and adolescents are much needed. Moreover, research on the role of 5-HT in neural plasticity raises questions on possible risks associated with long-term use. However, at this point, the results of our study demonstrated that sertraline, with a dosage of between 25 and 100 mg, has no negative effects on attentional measures in pediatric patients, although it may negatively impact on verbal memory performance.
